<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12886">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444951</url>
  </required_header>
  <id_info>
    <org_study_id>MTA40</org_study_id>
    <nct_id>NCT00444951</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia</brief_title>
  <official_title>Evaluation of the Response to a Single Dose of Menactra® in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent (A, C, Y, W 135) and at Least One Dose of Bivalent (A, C) Meningococcal Polysaccharide Vaccine in Saudi Arabia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>Saudi Arabia: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted among adolescents in Saudi Arabia who previously received one
      dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine.
      This study will evaluate the booster administration of Menactra® (Meningococcal A, C, Y, and
      W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine) compared with Mencevax®
      (Meningococcal A, C, Y, and W 135 Polysaccharide vaccine)in terms of their serum
      bactericidal antibody responses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination</measure>
    <time_frame>Baseline (Day 0) and Day 28 after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least a 4-Fold Rise in Titers Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Post-Menatcra® Vaccination</measure>
    <time_frame>Baseline (Day 0) and Day 28 After Vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Post-vaccination</measure>
    <time_frame>Day 0 to Day 7 Post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Neisseria Meningitidis</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Menactra® group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mencevax® group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have not previously received any meningococcal vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Menactra® group</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>Mencevax® group</arm_group_label>
    <other_name>Mencevax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, as determined by medical history and physical examination.

          -  Aged between 16 to 19 years on the day of inclusion (from 16th birthday to 1 day
             before 20th birthday inclusive).

          -  For the Menactra® and Mencevax® groups, one dose of quadrivalent (A, C, Y, W 135) and
             at least one dose of bivalent (A, C) meningococcal polysaccharide vaccine with no
             meningococcal vaccine received less than 2 years prior to enrollment.

          -  For the Control group, no previous history of any meningococcal vaccination.

          -  Informed consent form signed by the parent(s) or other legal representative for
             subject under 18 years and signed by subject him/herself if subject above 18 years
             old

          -  Able to provide a vaccination log or has available vaccination record in the Health
             Center

          -  Able to attend all scheduled visits and to comply with all trial procedures

        Exclusion Criteria:

          -  Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic,
             psychiatric, etc.)

          -  Known or suspected impairment of immunologic function.

          -  Acute medical illness with or without fever within the last 72 hours or an oral
             temperature ≥ 37.5°C at the time of inclusion.

          -  Administration of immune globulin or other blood products within the last three
             months, injected or oral corticosteroids or other immunomodulatory therapy within six
             weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids
             lasting &lt; 7 days may be included in the trial provided that they have not received
             more than one course within the last two weeks prior to enrollment.

          -  Oral or injected antibiotic therapy within the 72 hours prior to vaccination

          -  Received any vaccine in the 14-day period prior to study vaccination, or scheduled to
             receive any vaccination during the 14-day period after study vaccination.

          -  Previous history of documented invasive meningococcal disease.

          -  Systemic hypersensitivity to any of the vaccines components or history of a
             life-threatening reaction to the trial vaccines or a vaccine containing the same
             substances

          -  Participation in another clinical trial in the 4 weeks preceding the trial
             vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Any condition, which, in the opinion of the investigator, would pose a health risk to
             the subject, or interfere with the evaluation of the vaccine.

          -  Personal or family history of Guillain Barré syndrome.

          -  For female, known or suspected to be pregnant at the time of inclusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Helal Ahmar</city>
        <state>Mecca</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iskan</city>
        <state>Mecca</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>AlKhaleej</city>
        <state>Qassim</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>AlRabwa</city>
        <state>Qassim</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>S. Buraida</city>
        <state>Qassim</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safra-Al Midhnab</city>
        <state>Qassim</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Makkah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <reference>
    <citation>Khalil M, Al-Mazrou Y, Findlow H, Chadha H, Bosch Castells V, Oster P, Borrow R. Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine. Vaccine. 2014 Sep 29;32(43):5715-21. doi: 10.1016/j.vaccine.2014.08.026. Epub 2014 Aug 20.</citation>
    <PMID>25151042</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 16, 2015</lastchanged_date>
  <firstreceived_date>March 7, 2007</firstreceived_date>
  <firstreceived_results_date>February 9, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N meningitidis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 17 February 2007, to 01 July 2007, in 7 clinic centers in Saudi Arabia.</recruitment_details>
      <pre_assignment_details>A total of 450 participants who met the inclusion and exclusion criteria were enrolled, and 446 were vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Menactra® Group</title>
          <description>Participants have received previously a dose of an A, C, Y, W-135 vaccine and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, received a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.</description>
        </group>
        <group group_id="P2">
          <title>Mencevax® Group</title>
          <description>Participants who had previously been given 1 dose of quadrivalent (A, C, Y, W-135) and at least 1 dose of bivalent (A, C) meningococcal polysaccharide vaccine received a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>Participants who had not previously been given any meningococcal vaccine received 1 dose of Menactra®, meningococcal (serogroups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Menactra® Group</title>
          <description>Participants have received previously a dose of an A, C, Y, W-135 vaccine and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, received a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.</description>
        </group>
        <group group_id="B2">
          <title>Mencevax® Group</title>
          <description>Participants who had previously been given 1 dose of quadrivalent (A, C, Y, W-135) and at least 1 dose of bivalent (A, C) meningococcal polysaccharide vaccine received a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>Participants who had not previously been given any meningococcal vaccine received 1 dose of Menactra®, meningococcal (serogroups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="145"/>
                <measurement group_id="B2" value="142"/>
                <measurement group_id="B3" value="163"/>
                <measurement group_id="B4" value="450"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="110"/>
                <measurement group_id="B2" value="115"/>
                <measurement group_id="B3" value="134"/>
                <measurement group_id="B4" value="359"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="29"/>
                <measurement group_id="B4" value="91"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17.90" spread="1.20"/>
                <measurement group_id="B2" value="17.77" spread="1.15"/>
                <measurement group_id="B3" value="17.85" spread="1.15"/>
                <measurement group_id="B4" value="17.84" spread="1.16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="78"/>
                <measurement group_id="B2" value="78"/>
                <measurement group_id="B3" value="53"/>
                <measurement group_id="B4" value="209"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
                <measurement group_id="B2" value="64"/>
                <measurement group_id="B3" value="110"/>
                <measurement group_id="B4" value="241"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Saudi Arabia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="145"/>
                <measurement group_id="B2" value="142"/>
                <measurement group_id="B3" value="163"/>
                <measurement group_id="B4" value="450"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination</title>
        <time_frame>Baseline (Day 0) and Day 28 after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Geometric mean titers were evaluated in participants who received vaccine injection (full analysis set population).</population>
        <group_list>
          <group group_id="O1">
            <title>Menactra® Group</title>
            <description>Participants have received previously a dose of an A, C, Y, W-135 vaccine and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, received a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Mencevax® Group</title>
            <description>Participants who had previously been given 1 dose of quadrivalent (A, C, Y, W-135) and at least 1 dose of bivalent (A, C) meningococcal polysaccharide vaccine received a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Participants who had not previously been given any meningococcal vaccine received 1 dose of Menactra®, meningococcal (serogroups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="144"/>
                  <measurement group_id="O2" value="141"/>
                  <measurement group_id="O3" value="161"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination</title>
            <units>Titers (1/dil)</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="651.5" lower_limit="496.4" upper_limit="854.9"/>
                  <measurement group_id="O2" value="889.7" lower_limit="699.5" upper_limit="1131.5"/>
                  <measurement group_id="O3" value="441.1" lower_limit="327.8" upper_limit="593.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup A (Day 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4116.3" lower_limit="3468.7" upper_limit="4884.9"/>
                  <measurement group_id="O2" value="3833.4" lower_limit="3308.4" upper_limit="4441.7"/>
                  <measurement group_id="O3" value="6351.6" lower_limit="5508.3" upper_limit="7324.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.7" lower_limit="9.9" upper_limit="22.0"/>
                  <measurement group_id="O2" value="15.8" lower_limit="10.4" upper_limit="23.8"/>
                  <measurement group_id="O3" value="16.8" lower_limit="11.1" upper_limit="25.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (Day 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="288.3" lower_limit="190.2" upper_limit="437.0"/>
                  <measurement group_id="O2" value="158.6" lower_limit="99.7" upper_limit="252.0"/>
                  <measurement group_id="O3" value="993.4" lower_limit="714.5" upper_limit="1381.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.8" lower_limit="49.7" upper_limit="125.0"/>
                  <measurement group_id="O2" value="73.4" lower_limit="44.7" upper_limit="120.7"/>
                  <measurement group_id="O3" value="16.8" lower_limit="11.1" upper_limit="25.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (Day 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2770.1" lower_limit="2197.0" upper_limit="3492.6"/>
                  <measurement group_id="O2" value="1936.3" lower_limit="1425.7" upper_limit="2629.8"/>
                  <measurement group_id="O3" value="4204.6" lower_limit="3458.2" upper_limit="5112.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W-135 (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.5" lower_limit="11.8" upper_limit="29.0"/>
                  <measurement group_id="O2" value="24.5" lower_limit="15.2" upper_limit="39.6"/>
                  <measurement group_id="O3" value="8.1" lower_limit="5.6" upper_limit="11.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W-135 (Day 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2435.5" lower_limit="1714.7" upper_limit="3459.3"/>
                  <measurement group_id="O2" value="1455.7" lower_limit="958.1" upper_limit="2211.7"/>
                  <measurement group_id="O3" value="6926.7" lower_limit="5647.9" upper_limit="8495.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least a 4-Fold Rise in Titers Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Post-Menatcra® Vaccination</title>
        <time_frame>Baseline (Day 0) and Day 28 After Vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>4-Fold rise titers were determined in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Menactra® Group</title>
            <description>Participants have received previously a dose of an A, C, Y, W-135 vaccine and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, received a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Mencevax® Group</title>
            <description>Participants who had previously been given 1 dose of quadrivalent (A, C, Y, W-135) and at least 1 dose of bivalent (A, C) meningococcal polysaccharide vaccine received a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Participants who had not previously been given any meningococcal vaccine received 1 dose of Menactra®, meningococcal (serogroups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="136"/>
                  <measurement group_id="O3" value="160"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With At Least a 4-Fold Rise in Titers Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Post-Menatcra® Vaccination</title>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Serogroup A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="62"/>
                  <measurement group_id="O3" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="69"/>
                  <measurement group_id="O3" value="96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W-135</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                  <measurement group_id="O2" value="72"/>
                  <measurement group_id="O3" value="96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Post-vaccination</title>
        <time_frame>Day 0 to Day 7 Post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety analysis was on all vaccinated participants, intend-to-treat population (Safety analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>Menactra® Group</title>
            <description>Participants have received previously a dose of an A, C, Y, W-135 vaccine and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, received a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Mencevax® Group</title>
            <description>Participants who had previously been given 1 dose of quadrivalent (A, C, Y, W-135) and at least 1 dose of bivalent (A, C) meningococcal polysaccharide vaccine received a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Participants who had not previously been given any meningococcal vaccine received 1 dose of Menactra®, meningococcal (serogroups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="144"/>
                  <measurement group_id="O2" value="141"/>
                  <measurement group_id="O3" value="160"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Post-vaccination</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Solicited Injection Site Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                  <measurement group_id="O2" value="71"/>
                  <measurement group_id="O3" value="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Injection Site Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="66"/>
                  <measurement group_id="O3" value="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Injection Site Pain (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Injection Site Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Injection Site Erythema (≥ 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Injection Site Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Injection Site Swelling (≥ 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Solicited Systemic Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                  <measurement group_id="O2" value="86"/>
                  <measurement group_id="O3" value="90"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever (&gt; 39.0 ºC)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="64"/>
                  <measurement group_id="O3" value="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache (Prevents daily activities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="55"/>
                  <measurement group_id="O3" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Malaise (Prevents daily activities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="55"/>
                  <measurement group_id="O3" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia (Prevents daily activities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 to 1 month post-vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Menactra® Group</title>
          <description>Participants have received previously a dose of an A, C, Y, W-135 vaccine and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, received a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Mencevax® Group</title>
          <description>Participants who had previously been given 1 dose of quadrivalent (A, C, Y, W-135) and at least 1 dose of bivalent (A, C) meningococcal polysaccharide vaccine received a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>Participants who had not previously been given any meningococcal vaccine received 1 dose of Menactra®, meningococcal (serogroups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Perianal abcess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="61" subjects_affected="61" subjects_at_risk="142"/>
                <counts group_id="E2" events="55" subjects_affected="55" subjects_at_risk="138"/>
                <counts group_id="E3" events="61" subjects_affected="61" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="85" subjects_affected="85" subjects_at_risk="142"/>
                <counts group_id="E2" events="66" subjects_affected="66" subjects_at_risk="138"/>
                <counts group_id="E3" events="95" subjects_affected="95" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="142"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="138"/>
                <counts group_id="E3" events="42" subjects_affected="42" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="142"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="138"/>
                <counts group_id="E3" events="34" subjects_affected="34" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="142"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="138"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="142"/>
                <counts group_id="E2" events="55" subjects_affected="55" subjects_at_risk="138"/>
                <counts group_id="E3" events="72" subjects_affected="72" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="66" subjects_affected="66" subjects_at_risk="142"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="138"/>
                <counts group_id="E3" events="60" subjects_affected="60" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
